Stockscreener 앱 받기
2.71
2.17%
-0.06
시간 외 거래:
2.71
전일 마감가:
$2.77
열려 있는:
$2.81
하루 거래량:
101.20K
Relative Volume:
0.27
시가총액:
$56.61M
수익:
-
순이익/손실:
$-94.11M
주가수익비율:
-0.4509
EPS:
-6.01
순현금흐름:
$-86.06M
1주 성능:
-0.73%
1개월 성능:
+20.44%
6개월 성능:
-38.41%
1년 성능:
-66.83%
1일 변동 폭
$2.6757
$2.89
1주일 범위
$2.58
$2.9949
52주 변동 폭
$1.78
$8.58
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
명칭
Adverum Biotechnologies Inc
전화
(650) 649-1004
주소
100 CARDINAL WAY, REDWOOD CITY, CA
ADVM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.71 | 57.03M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 업그레이드 | Truist | Hold → Buy |
| 2021-07-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | 다운그레이드 | Truist | Buy → Hold |
| 2020-12-16 | 개시 | UBS | Neutral |
| 2020-11-12 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-05 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | 재확인 | Chardan Capital Markets | Neutral |
| 2019-09-13 | 재확인 | Chardan Capital Markets | Neutral |
| 2019-06-14 | 재개 | Raymond James | Mkt Perform |
| 2018-11-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-30 | 개시 | SunTrust | Buy |
| 2018-02-15 | 재개 | Piper Jaffray | Overweight |
| 2017-10-12 | 개시 | Raymond James | Outperform |
모두보기
Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스
What drives Adverum Biotechnologies Inc. stock priceConsistently superior profits - PrintWeekIndia
Adverum Biotechnologies Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia
What analysts say about Adverum Biotechnologies Inc. stockHigh-velocity gains - Autocar Professional
Is Adverum Biotechnologies Inc. a good long term investmentUnstoppable trading performance - Autocar Professional
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream - GlobeNewswire Inc.
How Adverum Biotechnologies Inc. stock performs during market volatilityFree Access to Investment Community - Newser
what makes adverum biotechnologies inc. stock price move sharplyDaily Volume Leaders - Newser
What makes Adverum Biotechnologies Inc. stock price move sharplyFree Access to Community - Newser
Why Adverum Biotechnologies Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser
Adverum Biotechnologies Up 22%, Insiders Still Down After US$526.8k Purchase - simplywall.st
Reversal Of Fortune For Adverum Biotechnologies Insiders Who Made A US$526.8k Purchase - Yahoo Finance
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from Russell 3000 Index - MarketScreener
Adverum Biotechnologies shareholders approve stock option repricing - Investing.com
Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India
Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World
Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan
Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks
Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus
Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider
Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph
Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan
Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX
Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com
Adverum Biotechnologies Inc (ADVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
0.31%
자본화:
|
볼륨(24시간):